**ORIGINAL ARTICLE**

# Is disposable continuous positive airway pressure system effective for the management of acute hypercapnic respiratory failure?

Erdem Cevik[1] · Deniz Dogan[2] · Kursat Gumus[3] · Derya Can[4] · Yahya A. Acar[3]

## Abstract

**Aim** This study aimed to investigate the effectiveness of disposable continuous positive airway pressure (DCPAP) system in decreasing the partial pressure of carbon dioxide ($P_aCO_2$) levels in patients with acute hypercapnic respiratory failure (AHRF).

**Material and methods** This retrospective observational study included patients treated in the emergency department (ED) with respiratory distress and $P_aCO_2 > 45$ mmHg. Patients were divided into two groups (DCPAP and non-DCPAP), depending on the treatment received to treat AHRF. The difference between the baseline $P_aCO_2$ levels in the first blood gas obtained from patients at the time of admission and the follow-up blood gas after treatment. Then, the calculated $P_aCO_2$ decrease was divided by the time elapsed to obtain the rate of decrease in $PaCO_2$ levels in mmHg/min. The statistical analyses were performed using SPSS version 18.0 software. A $p$ value of $< 0.05$ was considered statistically significant.

**Results** A total of 61 patients were included in the study, 31 patients in the DCPAP group and 30 patients in the non-DCPAP group. The mean age of the patients was $74.03 \pm 10.04$, and the male/female was 23/38. The study demonstrated a statistically significant difference between the DCPAP and non-DCPAP groups in terms of $P_aCO_2$ decreasing rate, and it was found to be twice higher in the DCPAP group ($0.11 \pm 0.07$ mmHg/min) than in the non-DCPAP group ($0.05 \pm 0.06$ mmHg/min).

**Conclusion** The study demonstrated that the treatment of AHRF patients with a DCPAP provides a faster decrease in $P_aCO_2$ levels in hypercapnic patients compared to standard medical therapy alone.

**Keywords** Carbon dioxide · Continuous positive airway pressure · Dyspnea · Hypercapnia · Noninvasive ventilation

## Introduction

Hypercapnia is defined as partial pressure of carbon dioxide ($P_aCO_2$) level over 45 mmHg (6 kPa), and it has a close relationship with respiratory acidosis (pH $< 7.35$) and increased mortality. Acute-on-chronic obstructive pulmonary disease (COPD) exacerbation and acute cardiogenic pulmonary edema (ACPE) are critical life-threatening conditions encountered in the emergency department (ED) and are the leading causes of $CO_2$ retention [1]. Acute hypercapnic respiratory failure (AHRF) is caused by the increased dead space ventilation fails to meet the $CO_2$ emission.

Treatment options for the management of AHRF include standard medical therapy, supplemental oxygen, noninvasive ventilation (NIV), and endotracheal intubation. Supplemental oxygen is the primary component of standard medical therapy along with pharmacological treatment. However, if the patient does not respond to the standard medical therapy, including supplemental oxygen targeted to a saturation level of 88–92% within 1 h, additional therapeutic measures shall be considered if $PaCO_2$ persists $> 45$ mmHg [2].

Beyond the delivery of supplemental oxygen via a nasal cannula, NIV, or intubation are the options to be considered according to the patient's clinical condition. Similar to invasive mechanical ventilation (IMV), NIV increases alveolar

✉ Erdem Cevik
cevikerdem@yahoo.com

1  Faculty of Medicine, Department of Emergency Medicine, University of Health Sciences, 34668, Uskudar, Istanbul, Turkey

2  Gulhane School of Medicine, Department of Chest Medicine and Tuberculosis, University of Health Sciences, Ankara, Turkey

3  Gulhane School of Medicine, Department of Emergency Medicine, University of Health Sciences, Ankara, Turkey

4  Department of Emergency Medicine, Halil Sıvgın Cubuk State Hospital, Ankara, Turkey

ventilation, improves gas exchanges, and unloads the respiratory muscles, thus, reducing the work of breathing. NIV also reduces $PaCO_2$ levels and improves respiratory acidosis in patients with acute respiratory failure [3]. Including the NIV application to treat acute-on-chronic COPD exacerbations at home with persistent hypercapnia has been reported to reduce readmission and mortality rates [4]. Therefore, NIV has been recently used in AHRF treatment rather than invasive approaches. In addition to $O_2$ and medical therapy, NIV has been reported to reduce mortality, intubation rates, and hospitalization in patients with COPD and ACPE [1].

The NIV is a mechanical ventilation technique that does not require invasive airway management and includes two main modes: continuous positive airway pressure (CPAP) and biphasic positive airway pressure (BiPAP) [5]. Current literature has emphasized the clinical value of CPAP in the immediate treatment of type 1 (ACPE) and type 2 (AHRF) respiratory failure [6]. It has also been reported that CPAP reduces treatment costs and the risk of developing complications by reducing the need for endotracheal intubation and risks associated with the known complications of mechanical ventilation, in particular [7]. Therefore, CPAP mask application has been reported to be beneficial for the patients with ACPE or COPD exacerbations, but the number of studies on NIV in the use of ED is limited. [4, 8]

Several types of electronic equipment are available on the market to deliver NIV. But more recently, disposable CPAP (DCPAP) systems manufactured using a special valve system are also used successfully in the treatment of patients with $CO_2$ retention. The main important advantage of a DCPAP system over the conventional NIV electronic equipment is that it does not need an additional equipment; it can deliver CPAP therapy with only one oxygen gas source from an oxygen gas cylinder or the hospital oxygen system. With this feature, it enables the treatment of AHRF patients in the ED without requiring additional equipment. However, the number of ED-based studies investigating the effect of DCPAP system on hypercapnic AHRF patients is limited.

This study aimed to evaluate the decreasing rate in $PaCO_2$ levels by using a disposable DCPAP mask in patients with AHRF.

## Materials and methods

This retrospective study included patients who were admitted to the ED of the Tertiary Care Training and Research Hospital between September 1, 2016, and April 30, 2019, for respiratory distress and hypercapnia. This study was conducted in accordance with the 1989 Declaration of Helsinki and was approved by the local ethics committee. Study protocol was approved by the local Gulhane Training and Research Hospital Clinical Research Ethics Committee on June 11, 2019 (approval number 19/255). The ethics committee waived the requirement for patient informed consent because no patient recontact was established for the study and data were anonymized.

Ventilator support medical devices to be used to treat hypercapnia in patients with AHRF are selected according to the clinical evaluation of the emergency consultant, and DCPAP is one of these treatment methods. The standard medical therapy is initiated as a routine treatment protocol for patients with AHRF, and in cases where there is no response to the standard medical treatment and supplemental oxygen, NIV therapy is initiated in addition to medical treatment. In the hosting institution, electronic NIV devices are not routinely used, and a disposable CPAP system is our treatment of choice (Flow-Safe®, Mercury Medical Inc., FL, USA) for NIV routine treatment protocol.

For the treatment, DCPAP system is connected to an oxygen source (cylinder or wall), and then the CPAP mask is applied to the patient. The DCPAP system is based on fluid mechanics, with oxygen gas molecules accelerated through microchannels, generating turbulence and, hence, CPAP pressure. The desired CPAP pressure (5–13 cm $H_2O$) applied to the patient is proportional to the gas flow (8–15 LPM) and, therefore, titratable to the clinical needs.

Within the scope of hospital protocol, DCPAP application is started with 8 L/min $O_2$ support. At this flow rate, 5 cm$H_2O$ pressure is created, and the pressure is titrated by progressively increasing the $O_2$ flow rate according to the clinical needs of the patient. This process is continued until the patient's $P_aCO_2$ level reaches the target value.

### Patient selection

A retrospective chart review of patients who presented to the ED with dyspnea and whose $PaCO_2$ level in blood gas was above 45 mmHg was performed. Exclusion criteria were as follows: patients unable to tolerate DCPAP, those under the age of 18, pregnant women, patients with myocardial infarction, hypotension (blood pressure < 100/60 mmHg), hospital admission for trauma, patients with cardiorespiratory arrest, and those with missing data.

Patients who met the inclusion criteria were identified through a retrospective scan made using the electronic hospital information management system (eHIMS). All history, physical examination, diagnostic codes, treatment, and expenditures in the hosting ED were handled through HIMS. Among the patients who were admitted to the ED during the study period, those who were diagnosed with dyspnea (R06.0) were screened. Patients with $PaCO_2$ of > 45 mmHg at the time of admission and those whose control blood gas sample was analyzed in the ED were included. The treatments that patients received and status whether DCPAP was applied were also evaluated via HIMS. Patients who met the

criteria during the retrospective screening were included in the study, and the screening was ended when the number of patients required for the study according to power analysis was reached. Demographic data (age, gender, complaints of admission, comorbidities), complete blood count at the time of admission and controls, routine and cardiac markers, and blood gas parameters of the patients were recorded.

The difference between the baseline $PaCO_2$ levels in the first blood gas obtained from patients at the time of admission and $PaCO_2$ levels in the follow-up blood gas was recorded in mmHg, and $PaCO_2$ change was divided by the time elapsed (minutes) to calculate the primary outcome of the study. According to the hospital protocol, blood gas sample is collected from patients who are followed in the ED due to shortness of breath before starting DCPAP treatment, and these are ordered via HIMS. In addition to the vital signs of the patients, blood gas is monitored at regular intervals, and the course of treatment is decided according to the decrease in pH and $PaCO_2$ levels in the blood gas. This study was based on the blood gas levels obtained when DCPAP was initiated, and the first control blood gas values during the treatment period as the duration may vary according to the patient. All the patients in the DCPAP group received the CPAP therapy with standard devices (Flow-Safe®, Mercury Medical Inc., FL, USA).

## Statistical analysis

Demographic data were expressed as frequency and percentage. Continuous variables were reported as means with standard deviation for normally distributed continuous variables, while non-normally distributed continuous variables were presented as medians with interquartile ranges (IQR). A chi-square test was used for the comparison of two groups in terms of categorical variables. Mann–Whitney $U$ test was used for pairwise comparison of continuous data that did not follow a normal distribution, whereas Student's $t$-test was used for pairwise comparison of continuous data following a normal distribution. The statistical analyses were performed using SPSS version 18.0 software. A $p$ value of $< 0.05$ was considered statistically significant.

## Results

A total of 61 patients were included in the study and retrospectively divided in 2 groups depending on whether they received medical therapy and oxygen alone or in conjunction with CPAP therapy. Thirty-one patients were included in the DCPAP group and 30 patients in the non-DCPAP group. The flowchart of the study is shown in Fig. 1. A total of 23 (37.7%) patients were male, and 38 (62.3%) were female with a mean age of $74.03 \pm 10.04$ years. There



**Fig. 1** Flowchart of the study (DCPAP: disposable continuous positive airway pressure mask system)

was no difference between the groups in terms of age and gender (Table 1).

There was no difference between the groups in terms of known cardiac comorbidities ($P = 0.202$, 0.731, and 0.795, respectively; chi-square test). A total of 41 (67.2%) were hospitalized, whereas 20 (32.8%) patients were discharged after treatment in ED. No significant difference was observed between the groups in terms of hospitalization rates. Length of stay in the ED was found to be 7 h (IQR: 5–8) for the DCPAP group, whereas it was 8 h (IQR: 5–8) for the non-DCPAP group. The length of hospital stay was 6 days (IQR: 4–7) for the DCPAP group and 5 days (IQR: 4–7) for the non-DCPAP group. Table 2 presents the vital signs of patients and their intergroup

**Table 1** Comparison of demographic data of groups

| Parameter | DCPAP | n | Mean ± SD | 95% CI | p |
|---|---|---|---|---|---|
| Age | Non-DCPAP group | 30 | 74.07 ± 9.86 | − 5.12–5.26 | 0.067* |
| | DCPAP group | 31 | 74.00 ± 10.38 | | |
| Sex (male/female) | Non-DCPAP group | 9/21 | N/A | N/A | 0.169* |
| | DCPAP group | 14/17 | N/A | | |
| Hospitalization/discharge | Non-DCPAP group | 20/10 | N/A | N/A | 0.572* |
| | DCPAP group | 21/10 | N/A | | |
| Heart rate | Non-DCPAP group | 30 | 96.87 ± 15.35 | − 10.59–2.07 | 0.183* |
| | DCPAP group | 31 | 101.13 ± 8.54 | | |
| Systolic blood pressure (mmHg) | Non-DCPAP group | 30 | 129.67 ± 23.43 | − 1.46–18.08 | 0.094* |
| | DCPAP group | 31 | 121.35 ± 13.56 | | |
| Diastolic blood pressure (mmHg) | Non-DCPAP group | 30 | 82.03 ± 12.83 | − 8.89–2.18 | 0.230* |
| | DCPAP group | 31 | 85.39 ± 8.39 | | |
| $SaO_2$ | Non-DCPAP group | 30 | 80.17 ± 19.72 | 0.17–20.66 | 0.047* |
| | DCPAP group | 31 | 69.76 ± 20.26 | | |
| Respiratory rate | Non-DCPAP group | 30 | 20.83 ± 1.66 | − 4.69–(− 2.67) | < 0.001* |
| | DCPAP group | 31 | 24.52 ± 2.25 | | |
| Left ventricle ejection fraction | Non-DCPAP group | 30 | 49.30 ± 12.71 | − 2.11–10.07 | 0.196* |
| | DCPAP group | 31 | 45.32 ± 11.03 | | |
| $CO_2$ decreasing rate (mmHg/minute) | Non-DCPAP group | 30 | 0.05 ± 0.06 | − 0.09–(− 0.03) | < 0.001* |
| | DCPAP group | 31 | 0.11 ± 0.07 | | |

*DCPAP* disposable continuous positive airway pressure mask system, *CI* confidence interval, *SD* standard deviation

*Student's *t*-test

*Chi-square test

**Table 2** Comparison of laboratory findings at the time of admission of patients with acute hypercapnic respiratory failure in DCPAP and non-CPAP groups

| Parameter | DCPAP | n | Mean ± SD | 95% CI | p* |
|---|---|---|---|---|---|
| White blood cell count ($10^3$ cells/mL) | Non-DCPAP group | 30 | 12.17 ± 5.96 | − 2.36–2.98 | 0.820 |
| | DCPAP group | 31 | 11.87 ± 4.37 | | |
| Hemoglobin (g/dL) | Non-dCPAP group | 30 | 12.94 ± 1.87 | − 1.77–0.36 | 0.192 |
| | BCPAP group | 31 | 13.65 ± 2.26 | | |
| Hematocrit (%) | Non-DCPAP group | 30 | 41.99 ± 6.16 | − 3.37–2.99 | 0.903 |
| | DCPAP group | 31 | 42.19 ± 6.25 | | |
| Platelets ($10^3$ cells/mL) | Non-DCPAP group | 30 | 252.93 ± 89.06 | − 13.02–75.41 | 0.163 |
| | dCPAP group | 31 | 221.74 ± 83.51 | | |
| Glucose (mg/dL) | Non-BCPAP group | 30 | 176.07 ± 76.09 | − 27.09–49.35 | 0.562 |
| | DCPAP group | 31 | 164.94 ± 73.09 | | |
| Urea (mg/dL) | Non-DCPAP group | 30 | 69.30 ± 34.57 | − 3.26–24.63 | 0.131 |
| | DCPAP group | 31 | 58.61 ± 17.26 | | |
| Creatinine (mg/dL) | Non-DCPAP group | 30 | 1.15 ± 0.44 | − 0.15–0.24 | 0.660 |
| | DCPAP group | 31 | 1.10 ± 0.33 | | |
| Sodium (mmol/L) | Non-DCPAP group | 30 | 136.83 ± 4.14 | − 3.88–0.45 | 0.118 |
| | DCPAP group | 31 | 138.55 ± 4.29 | | |
| Potassium (mmol/L) | Non-DCPAP group | 30 | 4.81 ± 0.74 | − 0.22–0.49 | 0.449 |
| | DCPAP group | 31 | 4.68 ± 0.65 | | |

*DCPAP* disposable continuous positive airway pressure mask system, *CI* confidence interval, *SD* standard deviation

*Student's *t*-test

**Table 3** Comparison of liver functions at the time of admission, coagulation markers, and length of stay in the ED, and hospital of the patients with acute hypercapnic respiratory failure in DCPAP and non-DCPAP groups

| Parameter | DCPAP | $n$ | Median rank | $Z$ | $p$-value |
|---|---|---|---|---|---|
| AST (U/L) | Non-DCPAP group | 30 | 29.57 | $-0.621$ | 0.535 |
| | DCPAP group | 31 | 32.39 | | |
| ALT (U/L) | Non-DCPAP group | 30 | 31.65 | $-0.282$ | 0.778 |
| | DCPAP group | 31 | 30.37 | | |
| INR | Non-DCPAP group | 30 | 31.32 | $-0.137$ | 0.891 |
| | DCPAP group | 31 | 30.69 | | |
| PTT | Non-DCPAP group | 30 | 29.20 | $-0.780$ | 0.436 |
| | DCPAP group | 31 | 32.74 | | |
| Troponin | Non-DCPAP group | 30 | 31.72 | $-0.310$ | 0.756 |
| | DCPAP group | 31 | 30.31 | | |
| ProBNP | Non-DCPAP group | 30 | 30.75 | $-0.108$ | 0.914 |
| | DCPAP group | 31 | 31.24 | | |
| Emergency department Length of stay (hours) | Non-DCPAP group | 30 | 31.63 | $-0.295$ | 0.789 |
| | DCPAP group | 31 | 30.39 | | |
| Length of stay in hospital (days) | Non-DCPAP group | 20 | 18.05 | $-0.290$ | 0.772 |
| | DCPAP group | 16 | 19.06 | | |

*DCPAP* disposable continuous positive airway pressure mask system, *BNP* brain natriuretic peptide, *AST* aspartate aminotransferase, *ALT* alanine aminotransferase, *INR* international normalized ratio, *PTT* prothrombin time

comparison. No difference was observed between the groups in terms of waiting time in ED and length of hospital stay (Table 3).

In both groups, it was observed a significant improvement in pH and $PaCO_2$ values after treatment ($P < 0.001$; paired samples $t$-test), whereas no statistically significant difference was observed for $HCO_3$ ($P = 0.190$; paired samples $t$-test). Noteworthy, there was a statistically significant difference between the two groups in terms of $PaCO_2$ decreasing rate, which was found to be higher in the DCPAP group ($0.11 \pm 0.07$ mmHg/min) than in the control group ($0.05 \pm 0.06$ mmHg/min) (Table 4) (Fig. 2).

## Discussion

This study demonstrated that NIV performed using DCPAP system significantly improved hypercapnia levels and twice more rapidly in patients with AHRF compared to the patients that received standard medical therapy alone. To the best of our knowledge, this is the first study in the literature that primarily investigates the efficacy of DCPAP in the decreasing rate of $PaCO_2$ levels in the acute phase in patients with AHRF.

Emergency physicians should immediately perform an emergency evaluation and initiate medical treatment for

**Table 4** Comparison of blood gas test results at the time of admission and control of patients with acute hypercapnic respiratory failure in DCPAP and non-DCPAP groups

| | Groups | Admission | | | | Control | | | |
|---|---|---|---|---|---|---|---|---|---|
| | | $n$ | Mean $\pm$ SD | CI 95% | $p^*$ | $n$ | Mean $\pm$ SD | CI 95% | $p^*$ |
| pH | Non-DCPAP group | 30 | $7.27 \pm 0.09$ | $-0.05$–$0.08$ | 0.673 | 30 | $7.31 \pm 0.08$ | $-0.07$–$0.03$ | 0.358 |
| | DCPAP group | 31 | $7.25 \pm 0.15$ | | | 31 | $7.33 \pm 0.10$ | | |
| $PaCO_2$ | Non DCPAP group | 30 | $67.72 \pm 10.80$ | $-10.77$–$4.14$ | 0.377 | 30 | $58.09 \pm 11.16$ | $-2.49$–$12.21$ | 0.191 |
| | DCPAP group | 31 | $71.04 \pm 17.4$ | | | 31 | $53.23 \pm 16.87$ | | |
| $HCO_3$ | Non-DCPAP group | 30 | $27.32 \pm 6.26$ | $-5.06$–$1.81$ | 0.349 | 30 | $27.82 \pm 6.52$ | $-2.98$–$3.49$ | 0.874 |
| | DCPAP group | 31 | $28.94 \pm 7.11$ | | | 31 | $27.56 \pm 6.11$ | | |

*DCPAP* disposable continuous positive airway pressure mask system, *CI* confidence interval, *SD* standard deviation

*Student's $t$-test

**Fig. 2** Comparison of $PaCO_2$ decreasing rate (mmHg/minute) of patients with acute hypercapnic respiratory failure in DCPAP and non-DCPAP groups. (DCPAP: disposable continuous positive airway pressure mask system)

a patient diagnosed with hypercapnia. However, it is recommended to keep the target $SaO_2$ levels within the range of 88–92% since there is a risk of hypoxemia and oxygen-induced hypercapnia in such cases [1]. Therefore, mechanical ventilation should be evaluated if the response to the initial treatment is insufficient [9]. The efficacy of NIV in patients with ACPE has been reported to be similar to CPAP. [10] According to the results of the present study, it was concluded that DCPAP could be used as a practical NIV approach to treat patients with AHRF, improving $PaCO_2$, $SaO_2$, and pH.

In a recent study by Uz et al., DCPAP was compared to a conventional electronic NIV equipment in patients with hypoxemic respiratory failure. [11] The study concluded that the DCPAP system can be as effective as NIV in patients with ACPO, considering the overall improvement observed in the physiological blood gas and other parameters as well as the mortality and cost-related considerations. Due to its lightweight and ease of use, the DCPAP could be a treatment of choice in the emergency and prehospital settings where electronic NIV devices may not be available especially in lower-income countries.

In a study by Murphy et al., the mean age of patients presenting to the hospital with COPD attack has been reported to be $67 \pm 10$ years, with a male sex ratio of 53% and $PaCO_2$ levels of 59 mmHg [4]. The cohort in the current study is compatible with the literature in terms of demographic data. Patients with AHRF have been seen to apply to the ED in the fifth and seventh decades with a $PaCO_2$ level of about 60 mmHg.

The main component of DCPAP is a CPAP valve, whereby $O_2$ molecules from the $O_2$ system are accelerated through micro-channels to provide positive pressure. The

pressure that is titrated by the flow from the $O_2$ system using the mask and CPAP pressure at 10 cmH2O can be created when oxygen is delivered at a rate of 15 L/min. In a study on this topic, end-expiratory pressure levels of patients receiving DCPAP have been reported to be $9.3 \pm 0.3$ cmH2O. [12] In another study, it has been reported that an airway pressure of 2.5 to 12.5 cmH2O can be achieved using DCPAP in healthy adults [13]. DCPAP titrates the positive end-expiratory pressure (PEEP) levels with $O_2$ flow and shows the numerical PEEP without any electronic part.

The NIV requirement in COPD exacerbation has been reported to be associated with poor prognosis [4]. Noteworthy, CPAP application above 15 cmH2O may reduce cardiac output by 20–30% [3]. Therefore, the addition of NIV to standard oxygen and medical therapy in the early period is beneficial for patients with AHRF. It may be associated with a poor prognosis when not given in appropriate indications and appropriate doses. However, the standard NIV settings (median home ventilator settings) in electronic BiLevel CPAP devices can be recommended as follows: an inspiratory positive airway pressure (IPAP) of 24 cmH2O (IQR: 22–26), an expiratory positive airway pressure (EPAP) of 4 (IQR: 4–5) cmH2O, and a backup rate of 14 (IQR: 14–16) breaths per minute, which may seem relatively complicated to users [4]. The use of DCPAP in patients with AHRF in emergency settings can be an effective option as the pressure can be titrated via the oxygen gas flow (portable cylinder or stationary wall source), and it can be applied immediately and efficiently in an emergency medical intervention without requiring any additional equipment other than the oxygen source and DCPAP.

DCPAP can also be integrated into prehospital systems. In a study by Spijker et al., DCPAP has been reported to be used successfully in the prehospital management of patients with ACPE [8]. In this study, a significant increase (from 88 to 95%) has been reported to occur in the mean $SaO_2$ values in the prehospital period, whereas there was a slight decrease in pulse, systolic blood pressure, and diastolic blood pressure values. The median length of hospital stay was reported to be 4.6 (min–max: 1.5–20) and 5.1 (1.5–34) days in DCPAP and non-DCPAP groups, respectively [8]. Another interesting finding of this study was that DCPAP was applied in only 16% of patients. The authors have attributed the reason for this to the fact that the hospital staff prefers to use the mask in more severe cases. The median $SaO_2$ values of the DCPAP group were lower than that of the non-DCPAP group. Compatible with the literature findings, the vital signs of the patients in the DCPAP group at the time of admission were worse, and the respiratory rate was significantly higher in the present study. The reason for this difference has been attributed to the fact that DCPAP was applied for patients with poor clinical status and unresponsive to primary treatment.

In a recent study, DCPAP has been reported to be quickly and successfully applied by nurses working in the ambulance without the need of a physician [14]. In patients with ACPE, median $SaO_2$ values have been reported to increase from 79% (69–94%) to 96% (89–98%) within 20 min using DCPAP adjusted to a standard 15 L/min flow and 5 cmH2O pressure, and ambulance staff has been reported to be satisfied with DCPAP treatment [14]. Similarly, in another study by Dieperink et al. involving patients in the coronary care unit, it has been reported that the $SaO_2$ values of the DCPAP group are lower than that of the non-DCPAP group, and the DCPAP system is a simple, effective, and cost-effective treatment approach [15]. These data suggest that DCPAP may be a useful device in the treatment of patients with acute respiratory failure, particularly in the ED as well as prehospital settings.

## Limitations

Our study was a single-center study done with a small sample size, and it was a retrospective study. This study lacked a regular CPAP group. There is a need for large, multicentric, prospective ED-based studies.

## Conclusion

This study showed that DCPAP is a method that can be used in the ED as it is easy to apply and lightweight, does not require additional equipment, and can provide rapid improvement of $PaCO_2$ levels.

## Declarations

**Ethics approval** This study was conducted in accordance with the 1989 Declaration of Helsinki and was approved by the local ethics committee. Study protocol was approved by Gulhane Training and Research Hospital Clinical Research Ethics Committee on June 11, 2019 (approval number 19/255).

**Conflict of interest** The authors declare no competing interests.

**Prior publiction** This manuscript has not been published and is not under consideration for publication elsewhere. The manuscript has not been presented in any congress.

## References

1. Pisani L, Corcione N, Nava S (2016) Management of acute hypercapnic respiratory failure. Curr Opin Crit Care 22:45–52

2. Thille AW, Frat JP (2018) Noninvasive ventilation as acute therapy. Curr Opin Crit Care 24:519–524

3. Kallet RH, Diaz JV (2009) The physiologic effects of noninvasive ventilation. Respir Care 54:102–115

4. Murphy PB, Rehal S, Arbane G et al (2017) Effect of home noninvasive ventilation with oxygen therapy vs oxygen therapy alone on hospital readmission or death after an acute COPD exacerbation: a randomized clinical trial. JAMA 317:2177–2186

5. Gaszynska E, Roguszka K, Stankiewicz-Rudnicki M et al (2013) Comparison of haemodynamic effects of noninvasive ventilation delivered via ResQGARD and CPAP boussignac masks. Pol Przegl Chir 85:129–132

6. Belenguer-Muncharaz A, Mateu-Campos L, Gonzalez-Luis R et al (2017) Non-invasive mechanical ventilation versus continuous positive airway pressure relating to cardiogenic pulmonary edema in an intensive care unit. Arch Bronconeumol 53:561–567

7. Sinuff T, Keenan SP (2004) Department of Medicine MU. Clinical practice guideline for the use of noninvasive positive pressure ventilation in COPD patients with acute respiratory failure. J Crit Care 19:82–91

8. Spijker EE, de Bont M, Bax M et al (2013) Practical use, effects and complications of prehospital treatment of acute cardiogenic pulmonary edema using the Boussignac CPAP system. Int J Emerg Med 6:8

9. Abdo WF, Heunks LM (2012) Oxygen-induced hypercapnia in COPD: myths and facts. Crit Care 16:323

10. Nouira S, Boukef R, Bouida W et al (2011) Non-invasive pressure support ventilation and CPAP in cardiogenic pulmonary edema: a multicenter randomized study in the emergency department. Intensive Care Med 37:249–256

11. Uz I, Kiyan GS, Ozcete E et al (2021) Is the flow-safe disposable continuous positive airway pressure (CPAP) system as effective as non-invasive mechanical ventilation (NIMV) in the treatment of acute cardiogenic pulmonary oedema? Am J Emerg Med 39:109–113

12. Moritz F, Benichou J, Vanheste M et al (2003) Boussignac continuous positive airway pressure device in the emergency care of acute cardiogenic pulmonary oedema: a randomized pilot study. Eur J Emerg Med 10:204–208

13. Sehlin M, Tornell SS, Ohberg F et al (2011) Pneumatic performance of the Boussignac CPAP system in healthy humans. Respir Care 56:818–826

14. Dieperink W, Weelink EE, van der Horst IC et al (2009) Treatment of presumed acute cardiogenic pulmonary oedema in an ambulance system by nurses using Boussignac continuous positive airway pressure. Emerg Med J 26:141–144

15. Dieperink W, Jaarsma T, van der Horst IC et al (2007) Boussignac continuous positive airway pressure for the management of acute cardiogenic pulmonary edema: prospective study with a retrospective control group. BMC Cardiovasc Disord 7:40